AMENDMENTS TO THE CLAIMS

Please rewrite the claims as follows:

1. (Currently Amended) Compounds of Formula (I)

$$\begin{array}{c|c}
G & E \\
V \\
W \\
N & OH
\end{array}$$

$$\begin{array}{c}
OH \\
OH \\
OH \\
OH
\end{array}$$

$$\begin{array}{c}
OH \\
OH \\
OH
\end{array}$$

$$\begin{array}{c}
OH \\
OH
\end{array}$$

$$\begin{array}{c}
OH \\
OH
\end{array}$$

wherein

A is a group of the formula $-C(CH_3)=CHR^5$ or $-CH=CHR^5$, wherein R^5 is a heteroaryl- or a heteroarylalkyl group, heteroalkyl, heteroalkyl, heteroalkyl heteroarylalkyl group,

U is hydrogen, halogen, an $\underline{C_1-C_4}$ alkyl, $\underline{C_3-C_4-cycloalkyl}$, $\underline{C_1-C_4}$ heteroalkyl-,-trifluromethyl or \underline{COOH} , heteroalkyl-, heteroalkyl-, heteroalkyl-, heteroalkyl-group,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R¹ is a C₁-C₄-alkyl-, a C₂-C₄-alkenyl-, a C₂-C₄-alkinyl- or a C₃-C₄-cycloalkyl-group,

V-W is a group of formula CH₂CH or CH=C,

X is oxygen or a group of the formula NR², wherein R² is hydrogen, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, or C_1 - C_4 heteroalkyl,

an alkyl-, alkinyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkyl-, aralkyl- or heteroarylalkyl-group- and

R³ and R⁴ independently from each other represent hydrogen, C₁-C₄-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.


- 2. (Canceled)
- 3. (Original) Compounds according to claim 1, wherein A is a group of formula (II) or (III)

$$R^6 \longrightarrow N$$
(III)
 $R^6 \longrightarrow N$
(IIII)

wherein Q is sulphur, oxygen or NR^7 , wherein R^7 is hydrogen, C_1 - C_4 alkyl or C_1 - C_4 heteroalkyl, z is Nitrogen or CH and R^6 is OR^8 , NHR^8 , C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_2 - C_4 alkinyl or C_1 - C_6 heteroalkyl, wherein R^8 is hydrogen, C_1 - C_4 alkyl or C_1 - C_4 heteroalkyl.

4. (Previously Presented) Compounds according to claim 1, wherein X is oxygen or NH.

- 5. (Previously Presented) Compounds according to claim 1, wherein R¹ is methyl or ethyl.
- 6. (Previously Presented) Compounds according to claim 1, wherein R³ and R⁴ are methyl groups.
- 7. (Previously Presented) Compounds according to claim 1, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.
- 8. (Previously Presented) Compounds according to claim 1, wherein G-E is selected from the following groups:



- 9. (Previously Presented) Compounds according to claim 1, wherein V-W is CH₂CH.
- 10. (Previously Presented) Pharmaceutical compositions containing a compound, a pharmacologically acceptable salt, a solvate or a hydrate according to claim 1 or a prodrug of the compound, the salt, the solvate and/or the hydrate and optionally one of more carriers and/or one or more adjuvants and/or one or more diluents.
- 11. (Currently Amended) Method of treating a disease selected from the group consisting of breast, ovarian, lung and prostate cancer through administering a pharmaceutically effective amount Use of a compound or a pharmaceutical composition according to claim 1 for the treatment of cancer.
- 12. (Canceled)

13. (Withdrawn) Compounds of formula (IVa), (IVb), (Va) and (Vb),

wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. (Withdrawn) Use of a compound according to claim 13 for the synthesis of a compound of formula (I).